Eloxx Pharmaceuticals (ELOX) Shares Bought by Metropolitan Life Insurance Co. NY

Metropolitan Life Insurance Co. NY raised its stake in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 356.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,172 shares of the company’s stock after purchasing an additional 7,944 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Eloxx Pharmaceuticals were worth $122,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Eloxx Pharmaceuticals by 4.0% in the 3rd quarter. BlackRock Inc. now owns 1,090,970 shares of the company’s stock worth $18,591,000 after buying an additional 41,490 shares during the period. MetLife Investment Advisors LLC purchased a new stake in shares of Eloxx Pharmaceuticals in the 3rd quarter worth about $381,000. Vanguard Group Inc. grew its position in shares of Eloxx Pharmaceuticals by 60.0% in the 3rd quarter. Vanguard Group Inc. now owns 857,202 shares of the company’s stock worth $14,606,000 after buying an additional 321,328 shares during the period. Vanguard Group Inc grew its position in shares of Eloxx Pharmaceuticals by 60.0% in the 3rd quarter. Vanguard Group Inc now owns 857,202 shares of the company’s stock worth $14,606,000 after buying an additional 321,328 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Eloxx Pharmaceuticals by 51.5% in the 4th quarter. Rhumbline Advisers now owns 28,562 shares of the company’s stock worth $343,000 after buying an additional 9,707 shares during the period.

ELOX opened at $11.23 on Friday. Eloxx Pharmaceuticals has a 52-week low of $9.12 and a 52-week high of $24.60.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) last issued its quarterly earnings data on Friday, March 8th. The company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.03).

ELOX has been the topic of a number of recent research reports. HC Wainwright initiated coverage on shares of Eloxx Pharmaceuticals in a research report on Monday, December 24th. They issued a “neutral” rating and a $10.00 target price on the stock. Zacks Investment Research cut shares of Eloxx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $22.20.

ILLEGAL ACTIVITY NOTICE: “Eloxx Pharmaceuticals (ELOX) Shares Bought by Metropolitan Life Insurance Co. NY” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/eloxx-pharmaceuticals-elox-shares-bought-by-metropolitan-life-insurance-co-ny.html.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Story: Trading Strategy

Want to see what other hedge funds are holding ELOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eloxx Pharmaceuticals (OTCMKTS:ELOX).

Institutional Ownership by Quarter for Eloxx Pharmaceuticals (OTCMKTS:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.